The Synergistic Combination of Curcumin and Polydatin Improves Temozolomide Efficacy on Glioblastoma Cells

Glioblastoma (GBL) is one of the more malignant primary brain tumors; it is currently treated by a multimodality strategy including surgery, and radio- and chemotherapy, mainly consisting of temozolomide (TMZ)-based chemotherapy. Tumor relapse often occurs due to the establishment of TMZ resistance,...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-10, Vol.25 (19), p.10572
Main Authors: Serafino, Annalucia, Krasnowska, Ewa Krystyna, Romanò, Sabrina, De Gregorio, Alex, Colone, Marisa, Dupuis, Maria Luisa, Bonucci, Massimo, Ravagnan, Giampietro, Stringaro, Annarita, Fuggetta, Maria Pia
Format: Article
Language:English
Subjects:
Analysis
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Apoptosis
Apoptosis - drug effects
Autophagy
Autophagy - drug effects
Brain cancer
Brain Neoplasms - drug therapy
Brain Neoplasms - pathology
Brain tumors
Cancer
Cancer therapies
Cell Cycle - drug effects
Cell differentiation
Cell growth
Cell Line, Tumor
Cell Proliferation - drug effects
Cell Survival - drug effects
chemoresistance
Chemotherapy
curcumin
Curcumin - pharmacology
Cytotoxicity
Development and progression
DNA methylation
DNA repair
Drug dosages
Drug Synergism
Functional foods
Functional foods & nutraceuticals
glioblastoma
Glioblastoma - drug therapy
Glioblastoma - metabolism
Glioblastoma - pathology
Glioblastoma multiforme
Glioma
Glucosides - pharmacology
Humans
Medical prognosis
Morphology
Muscle proteins
polydatin
Resveratrol
Stilbenes - pharmacology
Temozolomide
Temozolomide - pharmacology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma (GBL) is one of the more malignant primary brain tumors; it is currently treated by a multimodality strategy including surgery, and radio- and chemotherapy, mainly consisting of temozolomide (TMZ)-based chemotherapy. Tumor relapse often occurs due to the establishment of TMZ resistance, with a patient median survival time of
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms251910572